That is DEFINITELY a question I would like an answer to.. Also, I would like to know...
1. With respect to the registration study, why do they think they would be successful going after patients who have failed Keytruda, when the interim data shows Progessive Disease for 5 of the 6 patients presented
2. Why was interim data not presented for a lot of the earlier patients? We see data for patient#26, but not #3